Form 4: Boston Scientific Director Fujimori Receives Annual Equity Award

Sentiment:

SEC Form 4 Filing


Director Yoshiaki Fujimori of Boston Scientific Corp. received an annual equity award of 2,901 shares of common stock on May 9, 2024.

Summary

  • Yoshiaki Fujimori, a director at Boston Scientific Corp, received an annual equity award on May 9, 2024.
  • The award consisted of 2,901 shares of common stock.
  • The shares vest in full upon the next annual meeting of stockholders.
  • The value of the award is approximately $215,000, based on the closing price of the common stock on the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

  • The equity award aligns the director's interests with those of the shareholders.
  • The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The shares will vest upon the next annual meeting of stockholders.

Industry Context

Equity awards are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

  • Director compensation packages vary widely across the medical device industry.
  • Companies like Medtronic and Abbott also utilize equity awards as part of their director compensation, but the specific amounts and vesting schedules differ based on company size, performance, and individual contributions.
  • Benchmarking against peer companies would provide a more detailed assessment of the competitiveness of this equity award.

Stakeholder Impact

  • The equity award aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
  • The award does not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

  • The shares will vest upon the next annual meeting of stockholders.

Key Dates

DateDescription
05/09/2024Date of the equity award transaction.
05/10/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.